Scinovex
articleTop 1% cited

Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation

Radiology · 2007 · Vol. 243(1) · pp. 148–157
Elizabeth A. SadowskiLindsey BennettMicah R. ChanAndrew L. WentlandAndrea L. GarrettRobert GarrettArjang Djamali

Abstract

A combination of factors, including altered kidney function, inflammatory burden, and exposure to gadolinium-based contrast agents may all play a role in development of NSF. Alternative imaging should be considered in patients with these factors. If use of a gadolinium-based agent is clinically indicated, the referring physician and patient should be informed of the potential risk of developing NSF.

Lanthanide and Transition Metal ComplexesAdvanced MRI Techniques and ApplicationsAtomic and Subatomic Physics ResearchMedicineNephrogenic systemic fibrosisGadodiamideMagnetic resonance imagingRenal functionIncidence (geometry)Institutional review boardInternal medicinePopulationContext (archaeology)

MeSH terms

AdolescentAdultAgedContrast MediaFemaleFibrosisGlomerular Filtration RateHumansMagnetic Resonance ImagingMaleMeglumineMiddle AgedOrganometallic CompoundsRetrospective StudiesRisk Factors
Citations
1,016
FWCI
89.51
field-weighted impact
References
27
Percentile
100%
vs. same field & year
Citations per year
Cited by
References
Leptin and renal disease
American Journal of Kidney Diseases · 2002 · 870 citations
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
Journal of the American Academy of Dermatology · 2006 · 541 citations
Nephrogenic Systemic Fibrosis
Journal of the American Society of Nephrology · 2006 · 1,378 citations
Related articles
Nephrogenic Systemic Fibrosis
Journal of the American Society of Nephrology · 2006 · 1,378 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.